Portal de Periódicos da CAPES

COVID-19 Treatment at a Glance

2020; Volume: 21; Issue: 6 Linguagem: Inglês

10.5152/turkthoracj.2020.20125

2149-2530

Hüseyin Arıkan, Dilek Karadoğan, Fatma Tokgöz Akyıl, Aycan Yüksel, Zehra Nur Töreyin, Canan Gündüz, Feride Marım, Tuğba Şişmanlar Eyüboğlu, Nagehan Emiralioğlu, Tuğba Ramaslı Gürsoy, İrem Şerifoğlu, Abdülsamet Sandal, Aslı Öncel, Berrin Er, Neslihan Kose, Dorina Esendağlı, Mina Hızal, Aslıhan Banu Er, Fatma Esra Günaydın, İlknur Kaya, Hilal Özakıncı, Ümran Özden Sertçelik, Hatice Çelik Tuğlu, Nilufer Aylin Acet Ozurk, Özlem Ataoğlu, Ahu Cerit Cakir, Hüseyin Toptay, Merve Erçelik, Elif Develi, Selman Celik, Fatma Gülsüm Karakaş, Halime Yıldırım, Damla Karadeniz Guven, Nazlı Çetin, Sumeyye Nur Aslan Kucukyurt, Mehmet Fatih Elverişli, Pınar Yıldız Gülhan, Metin Akgün,

SARS-CoV-2 and COVID-19 Research

As coronavirus disease 2019 (COVID-19) spreads across the world, the ongoing clinical trials are leading to a big race worldwide to develop a treatment that will help control the pandemic. Unfortunately, COVID-19 does not have any known effective treatment with reliable study results yet. In this pandemic, there is not a lot of time to develop a new specific agent because of the rapid spread of the disease. The process of developing a vaccine is long and requires hard work. Although the pathophysiology of the disease is not fully understood, some of the proposed treatment alternatives are based on old evidence and some have been used with the idea that they might work owing to their mechanism of action. The efficacy, reliability, and safety of the currently available treatment alternatives are therefore a matter of debate. Currently, the main therapies used in the treatment of COVID-19 are antiviral drugs and chloroquine/hydroxychloroquine. Other proposed options include tocilizumab, convalescent plasma, and steroids, but the mainstay of the treatment in intensive care units remains supportive therapies.